Potent and selective 2-naphthylsulfonamide substituted hydroxamic acid inhibitors of matrix metalloproteinase-13

详细信息    查看全文

• 作者：Ruben A.  ; Tommasi ; Sven  ; Weiler ; Leslie W.  ; McQuire ; Olivier  ; Rogel ; Mark  ; Chambers ; Kirk  ; Clark ; John  ; Doughty ; James  ; Fang ; Vishwas  ; Ganu ; Jonathan  ; Grob ; Ronald  ; Goldberg ; Robert  ; Goldstein ; Stacey  ; LaVoie ; Raviraj  ; Kulathila ; William  ; Macchia ; Richard  ; Melton ; Clayton  ; Springer ; Marc  ; Walker ; Jing  ; Zhang ; Lijuan  ; Zhu ; Michael  ; Shultz  ; ;   ; ^{michael.shultz@novartis.com}
• 关键词：Metalloproteinase ; Hydroxamic acids ; Enzyme inhibitor ; Arthritis
• 刊名：Bioorganic and Medicinal Chemistry Letters
• 出版年：2011
• 出版时间：1 November 2011
• 年：2011
• 卷：21
• 期：21
• 页码：6440-6445
• 全文大小：1017 K

文摘

The matrix metalloproteinase enzyme MMP-13 plays a key role in the degradation of type II collagen in cartilage and bone in osteoarthritis (OA). An effective MMP-13 inhibitor would provide a disease modifying therapy for the treatment of arthritis, although this goal still continues to elude the pharmaceutical industry due to issues with safety. Our efforts have resulted in the discovery of a series of hydroxamic acid inhibitors of MMP-13 that do not significantly inhibit MMP-2 (gelatinase-1). MMP-2 has been implicated in the musculoskeletal side effects resulting from pan-MMP inhibition due to findings from spontaneously occurring human MMP-2 deletions. Analysis of the SAR of hundreds of previously prepared hydroxamate based MMP inhibitors lead us to 2-naphthylsulfonamide substituted hydroxamates which exhibited modest selectivity for MMP-13 versus MMP-2. This Letter describes the lead optimization of 1 and identification of inhibitors exhibiting >100-fold selectivity for MMP-13 over MMP-2